Study Reveals Hypoglycemia Patterns in Type 1 Diabetes and Proposes New Glucagon Delivery Systems
Researchers analyzed continuous glucose monitor data from over 1,100 type 1 diabetes patients and found that 20-30% of low blood sugar episodes are follow-on events from inadequate treatment of prior episodes, with independent events lasting 79-108 minutes on average. The study notes that hypoglycemia kinetics vary significantly by patient history, severity, and time of day. The findings informed development of new solid glucagon formulations and microneedle patches designed for both daytime rapid treatment and nighttime autonomous release.
A bioRxiv preprint analyzed continuous glucose monitor data spanning 246 patient-years from 1,135 type 1 diabetes patients to characterize hypoglycemic episode patterns and inform glucagon therapy development. The analysis revealed that a substantial proportion of hypoglycemic episodes (20-30%) result from inadequate treatment of preceding events rather than new independent events, and that independent hypoglycemic episodes average 79-108 minutes in duration. The researchers found significant variation in hypoglycemia onset and persistence based on patient history, severity, and timing (day versus night). Using these insights, the team developed two complementary glucagon delivery systems: on-demand microneedle patches for rapid daytime treatment of mild hypoglycemia, and enzyme-driven responsive patches for autonomous nighttime glucagon release. In vitro testing demonstrated excellent stability, loading, and release kinetics for both systems, and animal studies showed their ability to treat hypoglycemia. The work highlights how real-world continuous glucose monitoring data can guide engineering of improved glucagon therapies.
What's missing
The preprint does not specify the timeline for human clinical trials of the proposed glucagon delivery systems, nor does it detail the specific patient populations studied (age range, disease duration, baseline glycemic control) or provide information on potential limitations such as patch adhesion, skin irritation, or cost considerations.
What different sources said
- bioRxivCenter
Kinetics of Hypoglycemia in Diabetes Patients Informs Development of New Modes of Glucagon Therapy
Related
Person dies from rare Murray Valley Encephalitis virus in Western Australia
A person has died after contracting Murray Valley Encephalitis, a rare mosquito-borne virus, while travelling in Western Australia's north, marking the first reported death from the virus in WA this year. The individual was likely exposed in early May in the West Kimberley region, about 2,000 kilometres north of Perth, before being transferred to a Perth hospital where they died. Health authorities are urging residents and tourists to protect themselves from mosquito bites as the region enters its peak tourism season, noting the virus can cause serious brain infection though complications remain rare.
Shigellosis outbreak in Wayanad rises to three confirmed cases; health officials launch investigation
A third student tested positive for shigellosis in Wayanad, Kerala, following an outbreak at Mar Baselios AUP School, bringing confirmed cases to three. The bacterial infection has caused symptoms in 473 people total, with 58 currently hospitalized, prompting health officials to investigate the source and implement stricter sanitation measures. The outbreak highlights concerns about water safety and food hygiene in the region, with authorities conducting well chlorination and inspections of food establishments.
Red-Light Therapy for Hair Loss: Clinical Evidence and Consumer Device Reviews
Wired published a 2026 guide reviewing red-light therapy devices for hair restoration, reporting that clinical studies suggest the treatment can increase blood circulation, reduce inflammation, and support hair follicle growth. Red-light therapy has emerged as an at-home alternative to traditional hair-loss treatments like topical remedies or surgical procedures. The guide matters because hair loss affects millions, and if clinically validated, at-home devices could democratize access to a non-invasive treatment option.